GB2502127A - Multivalent antibodies and in vivo methods for their production - Google Patents

Multivalent antibodies and in vivo methods for their production Download PDF

Info

Publication number
GB2502127A
GB2502127A GB1208708.6A GB201208708A GB2502127A GB 2502127 A GB2502127 A GB 2502127A GB 201208708 A GB201208708 A GB 201208708A GB 2502127 A GB2502127 A GB 2502127A
Authority
GB
United Kingdom
Prior art keywords
vertebrate
antibody
cell
domain
epitope binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1208708.6A
Other languages
English (en)
Other versions
GB201208708D0 (en
Inventor
E-Chiang Lee
Volker Germaschewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority to GB1208708.6A priority Critical patent/GB2502127A/en
Publication of GB201208708D0 publication Critical patent/GB201208708D0/en
Priority to SG11201405059XA priority patent/SG11201405059XA/en
Priority to EP13711120.9A priority patent/EP2831245A1/en
Priority to JP2015502440A priority patent/JP2015512635A/ja
Priority to PCT/GB2013/050683 priority patent/WO2013144567A1/en
Priority to EP22173215.9A priority patent/EP4116427A1/en
Priority to EP13723933.1A priority patent/EP2852672A2/en
Priority to CN201380038167.0A priority patent/CN104508135B/zh
Priority to SG11201406947RA priority patent/SG11201406947RA/en
Priority to PCT/GB2013/051280 priority patent/WO2013171505A2/en
Priority to JP2015512133A priority patent/JP2015519055A/ja
Publication of GB2502127A publication Critical patent/GB2502127A/en
Priority to US14/498,685 priority patent/US10251377B2/en
Priority to US14/543,359 priority patent/US10667501B2/en
Priority to US16/353,870 priority patent/US11297811B2/en
Priority to US16/869,416 priority patent/US20200267952A1/en
Priority to US17/707,060 priority patent/US20220295765A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB1208708.6A 2012-03-28 2012-05-17 Multivalent antibodies and in vivo methods for their production Withdrawn GB2502127A (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GB1208708.6A GB2502127A (en) 2012-05-17 2012-05-17 Multivalent antibodies and in vivo methods for their production
SG11201405059XA SG11201405059XA (en) 2012-03-28 2013-03-18 Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
EP13711120.9A EP2831245A1 (en) 2012-03-28 2013-03-18 Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
JP2015502440A JP2015512635A (ja) 2012-03-28 2013-03-18 クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
PCT/GB2013/050683 WO2013144567A1 (en) 2012-03-28 2013-03-18 Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
JP2015512133A JP2015519055A (ja) 2012-05-17 2013-05-17 二重特異性免疫グロブリンまたは超変異重鎖のみの免疫グロブリンのｉｎｖｉｖｏでの生成のためのトランスジェニック非ヒト脊椎動物
SG11201406947RA SG11201406947RA (en) 2012-05-17 2013-05-17 Transgenic non-human vertebrate for the in vivo production of dual specificity|immunoglobulins or hypermutated heavy chain only immunoglobulins
EP13723933.1A EP2852672A2 (en) 2012-05-17 2013-05-17 In vivo guided selection&antibodies
CN201380038167.0A CN104508135B (zh) 2012-05-17 2013-05-17 用于在体内产生双重特异性免疫球蛋白或者仅高变重链免疫球蛋白的转基因非人脊椎动物
EP22173215.9A EP4116427A1 (en) 2012-05-17 2013-05-17 In vivo guided selection & antibodies
PCT/GB2013/051280 WO2013171505A2 (en) 2012-05-17 2013-05-17 In vivo guided selection & antibodies
US14/498,685 US10251377B2 (en) 2012-03-28 2014-09-26 Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
US14/543,359 US10667501B2 (en) 2012-05-17 2014-11-17 Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins
US16/353,870 US11297811B2 (en) 2012-03-28 2019-03-14 Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
US16/869,416 US20200267952A1 (en) 2012-05-17 2020-05-07 Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins
US17/707,060 US20220295765A1 (en) 2012-03-28 2022-03-29 Transgenic Non-Human Vertebrate for the Expression of Class-Switched, Fully Human, Antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1208708.6A GB2502127A (en) 2012-05-17 2012-05-17 Multivalent antibodies and in vivo methods for their production

Publications (2)

Publication Number Publication Date
GB201208708D0 GB201208708D0 (en) 2012-07-04
GB2502127A true GB2502127A (en) 2013-11-20

Family

ID=46546244

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1208708.6A Withdrawn GB2502127A (en) 2012-03-28 2012-05-17 Multivalent antibodies and in vivo methods for their production

Country Status (7)

Country Link
US (2) US10667501B2 (https=)
EP (2) EP2852672A2 (https=)
JP (1) JP2015519055A (https=)
CN (1) CN104508135B (https=)
GB (1) GB2502127A (https=)
SG (1) SG11201406947RA (https=)
WO (1) WO2013171505A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2584219A (en) * 2014-10-22 2020-11-25 Crescendo Biologics Ltd Transgenic mice
GB2547587B (en) * 2014-10-22 2020-12-09 Crescendo Biologics Ltd Transgenic mice

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
BR112012000536A2 (pt) 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
JP6482757B2 (ja) 2010-07-26 2019-03-13 トリアンニ インコーポレイテッドＴｒｉａｎｎｉ，Ｉｎｃ． トランスジェニック動物および使用方法
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
PT3597037T (pt) 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
KR102276752B1 (ko) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
EP3271403A1 (en) * 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2017008169A1 (en) 2015-07-15 2017-01-19 Zymeworks Inc. Drug-conjugated bi-specific antigen-binding constructs
US20170058052A1 (en) * 2015-08-24 2017-03-02 Trianni, Inc. Enhanced production of immunoglobulins
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
AU2017213633B2 (en) 2016-02-04 2023-08-03 Trianni, Inc. Enhanced production of immunoglobulins
WO2017172981A2 (en) * 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
RU2020103379A (ru) 2017-07-04 2021-08-04 Куревак Аг Новые молекулы нуклеиновых кислот
CN111630173A (zh) 2017-10-19 2020-09-04 库瑞瓦格股份公司 新型人工核酸分子
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
WO2019190922A1 (en) * 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
KR20250121150A (ko) * 2018-03-26 2025-08-11 리제너론 파마슈티칼스 인코포레이티드 치료제를 시험하기 위한 인간화된 설치류
CN108486126A (zh) * 2018-03-27 2018-09-04 重庆金迈博生物科技有限公司 一种核酸分子及其在人源化抗体中的应用
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
EP3927832A4 (en) 2019-02-18 2022-11-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
CN113661173B (zh) 2019-03-29 2024-10-01 豪夫迈·罗氏有限公司 通过以限定的组织形式靶向整合多个表达盒来产生表达FcRn的细胞的方法
WO2020254352A1 (en) * 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
EP3990484A1 (en) * 2019-06-28 2022-05-04 F. Hoffmann-La Roche AG Method for the production of an antibody
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2021266706A1 (en) * 2020-05-05 2022-12-15 Regeneron Pharmaceuticals, Inc. Car comprising CD28 zeta and CD3 zeta
KR20230018439A (ko) 2020-06-02 2023-02-07 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 공동 경쇄 면역글로불린 좌위를 갖는 유전자 변형 비인간 동물
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
WO2022132943A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
JP7799706B2 (ja) * 2021-05-05 2026-01-15 レヴェラージェン，インコーポレーテッド 抗体を産生するための組換え非ヒト動物
CN117057015B (zh) * 2023-08-18 2025-05-02 国家海洋环境监测中心 海上风力发电结构极端荷载计算分析方法
EP4512243A1 (en) 2023-08-21 2025-02-26 Kymab Limited Binding molecules
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013852A1 (en) * 1995-10-10 1997-04-17 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO2002002781A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US20050048621A1 (en) * 2003-09-03 2005-03-03 Luigi Grasso Genetically altered antibody-producing cell lines with improved antibody characteristics
WO2007024715A2 (en) * 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
EP1780272A1 (en) * 2005-10-27 2007-05-02 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Method for enhancing somatic hypermutation, gene conversion and class switch recombination
WO2008103474A1 (en) * 2007-02-20 2008-08-28 Anaptysbio, Inc. Methods of generating libraries and uses thereof
WO2009009424A2 (en) * 2007-07-06 2009-01-15 Vaxdesign Corporation Rapid generation of t cell-independent antibody responses to t cell-dependent antigens
WO2009020923A1 (en) * 2007-08-03 2009-02-12 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
WO2009068649A2 (en) * 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
WO2011004192A1 (en) * 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules
WO2011008093A1 (en) * 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
EP2281845A1 (en) * 2008-04-25 2011-02-09 Kyowa Hakko Kirin Co., Ltd. Stable polyvalent antibody
WO2011056864A1 (en) * 2009-11-05 2011-05-12 Anaptysbio, Inc. Methods of generating improved antigen-binding agents using chain shuffling and optionally somatic hypermutation
WO2011158009A1 (en) * 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
WO2012063048A1 (en) * 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5169939A (en) 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US4720449A (en) 1985-06-03 1988-01-19 Polaroid Corporation Thermal imaging method
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
DE4228162C1 (de) 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
US5565321A (en) 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
DE4331162A1 (de) 1993-09-14 1995-03-16 Bayer Ag Verfahren zur Herstellung von Cyaninfarbstoffen
BE1007904A3 (nl) 1993-12-23 1995-11-14 Dsm Nv Werkwijze voor de bereiding van een alkanol en/of een alkanon.
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU3507297A (en) 1996-06-26 1998-01-14 Baylor College Of Medicine Chromosomal rearrangement by insertion of two recombination substrates
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6187994B1 (en) 1997-11-18 2001-02-13 Pioneer Hi-Bred International, Inc. Compositions and methods for genetic modification of plants
EP0939120A1 (en) 1998-02-27 1999-09-01 Gesellschaft für biotechnologische Forschung mbH (GBF) Method for marker-free repetitive DNA expression cassette exchange in the genome of cells or parts of cells
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
JP2003503015A (ja) 1999-05-03 2003-01-28 メダレツクス・インコーポレーテツド スタフィロコッカス・アウレウスに対するヒト抗体
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2307503A1 (en) 2000-05-02 2001-11-02 Carlos F. Barbas Iii Peptides for use as a vaccine or treatment for hiv infection
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
CA2416701A1 (en) 2000-07-21 2002-01-31 The United States Of America, As Represented By The Secretary Of Agricul Ture Methods for the replacement, translocation and stacking of dna in eukaryotic genomes
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60144305D1 (de) 2000-11-17 2011-05-05 Kyowa Hakko Kirin Co Ltd Expression von xenogenen (humanen) Immunglobulinen in klonierten, transgenen Huftieren
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
EP1409646B1 (en) 2000-12-19 2012-06-13 Altor BioScience Corporation Transgenic animals comprising a humanized immune system
BRPI0116728B1 (pt) 2001-01-05 2018-10-30 Pfizer Inc. anticorpos para receptor de fator de crescimento i semelhante à insulina
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
FR2827302B1 (fr) 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
CA2763913C (en) 2001-08-10 2014-10-28 Aberdeen University Antigen binding domains
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
ES2283368T3 (es) 2001-11-14 2007-11-01 Affimed Therapeutics Ag Anticuerpos biespecificos anti-cd19 y anti-cd16 y usos de los mismos.
US7435871B2 (en) 2001-11-30 2008-10-14 Amgen Fremont Inc. Transgenic animals bearing human Igλ light chain genes
WO2003061363A2 (en) 2002-01-17 2003-07-31 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
CA2496233A1 (en) 2002-09-09 2004-03-18 California Institute Of Technology Methods and compositions for the generation of humanized mice
EP1400534B1 (en) 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
US7700356B2 (en) 2002-11-08 2010-04-20 The United States Of America As Represented By The Secretary Of Agriculture System for gene targeting and producing stable genomic transgene insertions
DE10251918A1 (de) 2002-11-08 2004-05-19 Horn, Carsten, Dipl.-Biochem. Dr. Systeme zur Erzeugung stabiler genomischer Transgen-Insertionen
CL2003002461A1 (es) 2002-11-27 2005-01-07 Dow Chemical Company Agroscien Inmunoglobulina que comprende al menos un glicano afucosilado, composicion que la contiene, secuencia nucleotidica y vector que la comprende, procedimiento para producir dicha inmunoglobulina en plantas.
ES2273202T3 (es) 2003-01-07 2007-05-01 Symphogen A/S Procedimiento para producir proteinas policlonales recombinantes.
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
US7205148B2 (en) 2003-06-11 2007-04-17 Regeneron Pharmaceuticals, Inc. Genome mutation by intron insertion into an embryonic stem cell genome
GB2403475B (en) 2003-07-01 2008-02-06 Oxitec Ltd Stable integrands
US7993650B2 (en) 2003-07-04 2011-08-09 Affibody Ab Polypeptides having binding affinity for HER2
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
WO2005019463A1 (en) 2003-08-11 2005-03-03 Therapeutic Human Polyclonals, Inc. Improved transgenesis with humanized immunoglobulin loci
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7205140B2 (en) 2003-10-20 2007-04-17 Campusgen Gmbh Nucleotide sequence for creatinine deiminase and method of use
CN1946417A (zh) 2003-12-05 2007-04-11 阿德内克休斯治疗公司 2型血管内皮生长因子受体的抑制剂
RS53984B1 (sr) 2003-12-10 2015-10-30 E. R. Squibb & Sons L.L.C. Ip-10 antitela i njihove upotrebe
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2005092926A2 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
SI2311874T1 (sl) 2004-07-22 2017-12-29 Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics Vezavne molekule
FR2875239B1 (fr) 2004-09-10 2007-07-20 Inst Necker Ass Loi De 1901 Procede pour l'acceleration des mutations somatiques et son application en proteomique
CN101076542A (zh) 2004-09-13 2007-11-21 伊沃詹尼克斯有限公司 特异性针对肝细胞癌和其他癌的抗体及其用途
WO2006044492A2 (en) 2004-10-14 2006-04-27 Ingenious Targeting Laboratory, Inc. Methods for generating rat embryo-derived cell lines and genetic modification of rat genome
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
WO2006055704A2 (en) 2004-11-17 2006-05-26 Curagen Corporation Antibodies directed to ten-m proteins and uses thereof
BRPI0519596B1 (pt) 2004-12-21 2022-01-18 Astrazeneca Ab Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado
JP2008538912A (ja) 2005-04-29 2008-11-13 イナート・ファルマ 遺伝子導入動物および組換え抗体の製造方法
CN101297031B (zh) 2005-05-14 2013-06-05 复旦大学 在脊椎动物中作为遗传操作和分析工具的piggyBac
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
GB0601513D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding molecules 3
GB0601511D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding Molecules 2
TWI404727B (zh) 2006-01-25 2013-08-11 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 對偶基因排除
US7462759B2 (en) 2006-02-03 2008-12-09 Pioneer Hi-Bred International, Inc. Brittle stalk 2 gene family and related methods and uses
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
US7709257B2 (en) 2006-06-27 2010-05-04 Vax Design Corp. Models for vaccine assessment
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
EP2061812A4 (en) 2006-08-22 2010-06-09 G2 Inflammation Pty Ltd METHOD FOR THE PRODUCTION OF ANTIBODIES
CN101522716B (zh) 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
WO2008070367A2 (en) 2006-11-01 2008-06-12 Facet Biotech Corporation Mammalian cell-based immunoglobulin display libraries
US7556337B2 (en) * 2006-11-02 2009-07-07 Xerox Corporation System and method for evaluating line formation in an ink jet imaging device to normalize print head driving voltages
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
GB0700194D0 (en) 2007-01-05 2007-02-14 Univ Edinburgh Humanisation of animals
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
JP5642972B2 (ja) 2007-02-21 2014-12-17 ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
BRPI0809435A2 (pt) 2007-03-27 2014-09-09 Sea Lane Biotechnologies, Llc Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos
GB0706628D0 (en) * 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
HRP20100640T1 (hr) 2007-05-25 2010-12-31 Symphogen A/S Postupak proizvodnje rekombinantnog poliklonskog proteina
DK2602323T3 (en) 2007-06-01 2018-04-16 Open Monoclonal Tech Inc Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
US20090021474A1 (en) 2007-07-17 2009-01-22 Motorola, Inc. System and method for displaying status information of a multimedia broadcast receiver on an ambient device
NZ583019A (en) 2007-07-31 2011-05-27 Regeneron Pharma Human antibodies to human cd20 and method of using thereof
BRPI0815370B8 (pt) 2007-08-10 2021-05-25 Regeneron Pharma anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
CA2708776A1 (en) 2007-12-10 2009-06-18 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20110107445A1 (en) 2008-03-26 2011-05-05 Iti Scotland Limited Efficient Insertion of DNA Into Embryonic Stem Cells
WO2009129247A2 (en) 2008-04-14 2009-10-22 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
PL3456190T3 (pl) 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
EP2346994B1 (en) 2008-09-30 2022-02-16 Ablexis, LLC Knock-in mice for the production of chimeric antibodies
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP5827127B2 (ja) 2008-12-18 2015-12-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム ヒト化抗体を発現する非ヒトトランスジェニック動物及びその使用
WO2010091182A2 (en) 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
JP2012518398A (ja) * 2009-02-24 2012-08-16 グラクソ グループ リミテッド 抗原結合性構築物
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
CN102482639B (zh) 2009-04-03 2016-01-06 医学研究会 活化诱导胞苷脱氨酶(aid)突变体及使用方法
WO2010132872A1 (en) 2009-05-15 2010-11-18 Novimmune S.A Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
US9394374B2 (en) 2009-05-28 2016-07-19 Glaxo Group Limited Antigen-binding proteins
CA2763493A1 (en) 2009-05-28 2010-12-02 Glaxo Group Ltd. Antigen-binding proteins
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
KR101829073B1 (ko) 2009-06-26 2018-02-13 아이2 파마슈티컬스, 인크. 대리 경쇄의 발현
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8592644B2 (en) 2009-08-13 2013-11-26 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal CDRS
US20120233715A1 (en) 2009-11-17 2012-09-13 Kyowa Hakko Kirin Co., Ltd Human artificial chromosome vector
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
US8754287B2 (en) 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
SI2501817T2 (sl) 2010-02-08 2021-09-30 Regeneron Pharmaceuticals, Inc. Miš z navadno lahko verigo
JP6208580B2 (ja) 2010-05-17 2017-10-04 サンガモ セラピューティクス， インコーポレイテッド 新規のｄｎａ結合タンパク質及びその使用
US9012717B2 (en) 2010-06-22 2015-04-21 Regeneron Pharmaceuticals, Inc. Human lambda light chain mice
US8890233B2 (en) * 2010-07-06 2014-11-18 Macronix International Co., Ltd. 3D memory array with improved SSL and BL contact layout
EP2407487A1 (en) * 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
PL2606064T3 (pl) * 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
KR20130118925A (ko) 2010-12-22 2013-10-30 제넨테크, 인크. 항-pcsk9 항체 및 사용 방법
RU2722373C2 (ru) 2011-02-25 2020-05-29 Редженерон Фармасьютикалс, Инк. Мыши adam6
RS59728B1 (sr) 2011-08-05 2020-02-28 Regeneron Pharma Humanizovani miševi univerzalnog lakog lanca
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20160098514A (ko) 2011-10-17 2016-08-18 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
US20130102031A1 (en) 2011-10-25 2013-04-25 Anaptysbio, Inc. Use of somatic hypermutation to create insertion and deletion mutations in vitro
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
RU2664181C2 (ru) 2011-12-20 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной легкой цепью
RS62023B1 (sr) 2012-02-01 2021-07-30 Regeneron Pharma Humanizovani glodari koji eksprimiraju teške lance koji sadrže vl domene
HK1200463A1 (en) 2012-03-02 2015-08-07 瑞泽恩制药公司 Human antibodies to clostridium difficile toxins
IN2014DN08163A (https=) 2012-03-06 2015-05-01 Regeneron Pharma
MX2014011047A (es) 2012-03-16 2015-04-08 Regeneron Pharma Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph.
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
PT3597037T (pt) 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
DK2931897T3 (en) 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
EP2840892B1 (en) 2013-02-20 2018-04-18 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US20150033372A1 (en) 2013-05-01 2015-01-29 Kymab Limited Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US20140331344A1 (en) 2013-05-03 2014-11-06 Kymab Ltd. Transgenic Animals
US20140331339A1 (en) 2013-05-03 2014-11-06 Kymab Limited Transgenic Non-Human Assay Vertebrates, Assays and Kits
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
GB201710984D0 (en) 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013852A1 (en) * 1995-10-10 1997-04-17 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO2002002781A1 (en) * 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US20050048621A1 (en) * 2003-09-03 2005-03-03 Luigi Grasso Genetically altered antibody-producing cell lines with improved antibody characteristics
WO2007024715A2 (en) * 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
EP1780272A1 (en) * 2005-10-27 2007-05-02 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Method for enhancing somatic hypermutation, gene conversion and class switch recombination
WO2008103474A1 (en) * 2007-02-20 2008-08-28 Anaptysbio, Inc. Methods of generating libraries and uses thereof
WO2009009424A2 (en) * 2007-07-06 2009-01-15 Vaxdesign Corporation Rapid generation of t cell-independent antibody responses to t cell-dependent antigens
WO2009020923A1 (en) * 2007-08-03 2009-02-12 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
WO2009068649A2 (en) * 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs
EP2281845A1 (en) * 2008-04-25 2011-02-09 Kyowa Hakko Kirin Co., Ltd. Stable polyvalent antibody
WO2009143472A2 (en) * 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
WO2011004192A1 (en) * 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules
WO2011008093A1 (en) * 2009-07-15 2011-01-20 Aimm Therapeutics B.V. Means and methods for producing high affinity antibodies
WO2011056864A1 (en) * 2009-11-05 2011-05-12 Anaptysbio, Inc. Methods of generating improved antigen-binding agents using chain shuffling and optionally somatic hypermutation
WO2011158009A1 (en) * 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
WO2012063048A1 (en) * 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J Immunol Methods; Vol 316, pp 59-66 (2006). Iglesias-Ussel et al. "Forced expression of AID facilitates the isolation of class switch variants from hybridoma cells" *
Nature; Vol 416, pp 340-345 (2002). Okazaki et al. "The AID enzyme induces class switch recombination in fibroblasts" *
Proc Natl Acad Sci USA; Vol 78, pp 564-568 (1981). Burrows et al. "Expression of mu and gamma immunoglobulin heavy chains in different cells of a cloned mouse lymphoid cell line" *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2584219A (en) * 2014-10-22 2020-11-25 Crescendo Biologics Ltd Transgenic mice
GB2547587B (en) * 2014-10-22 2020-12-09 Crescendo Biologics Ltd Transgenic mice
GB2584219B (en) * 2014-10-22 2021-03-24 Crescendo Biologics Ltd Transgenic Mice
US11547099B2 (en) 2014-10-22 2023-01-10 Crescendo Biologies Limited Transgenic mice

Also Published As

Publication number Publication date
CN104508135A (zh) 2015-04-08
JP2015519055A (ja) 2015-07-09
WO2013171505A2 (en) 2013-11-21
EP2852672A2 (en) 2015-04-01
US10667501B2 (en) 2020-06-02
SG11201406947RA (en) 2014-11-27
WO2013171505A3 (en) 2014-01-03
EP4116427A1 (en) 2023-01-11
US20150133641A1 (en) 2015-05-14
CN104508135B (zh) 2017-09-22
US20200267952A1 (en) 2020-08-27
GB201208708D0 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
US20200267952A1 (en) Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins
JP7599427B2 (ja) 多量体
US11453726B2 (en) Multimers, tetramers and octamers
JP6706578B2 (ja) タンデム型Ｆａｂ免疫グロブリン及びその使用
TW201932600A (zh) 核酸之靶向整合
CN109563124A (zh) 多特异性抗体的纯化
JP2024177226A (ja) 対合していない可変ドメインを含む抗原結合分子
US20230183378A1 (en) Multimers, tetramers & octamers
US20240240156A1 (en) Combined transposon-mediated integration and targeted integration of nucleic acids into host cells
HK40086143A (en) In vivo guided selection & antibodies
WO2024094527A1 (en) Non-human vertebrates & cells
US20240240175A1 (en) Combinatorial vector cloning and transfection strategies for targeted integration of nucleic acids
HK40128447A (zh) 使用哺乳动物细胞产生异多聚体蛋白
HK40094067A (zh) 核酸的靶向整合
EP4126933A1 (en) Multimers for viral strain evolution

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1191036

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1191036

Country of ref document: HK

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)